NHR2 inhibitors
Treatment of AML by inhibitors of NHR2 and/or RUNX1/ETO-tetramerization provides a therapy option with a unique mode of action.
Compounds for treatment of AML
Unique mode of action
Medical use/compound protection achievable
In vivo data from mouse model available
Access to inventor know-how
Treatment of acute myeloid leukemia
The formation and onset of the prevalent form of acute myeloid leukemia (AML, FAB subtype M2) requires RUNX1/ETO, the product of the t(8;21) chromosomal translocation. Tetramerization through the nervy homology region 2 (NHR2) of ETO is essential for the RUNX1/ETO-mediated transformation. The inventors demonstrated that inhibition of NHR2 tetramerization by first-in-class small molecules is a viable entry point for the treatment of AML.
Licensing
25/04/2014 00:00:00
WO2014EP58449 20140425
- international:
C07C59/70
- cooperative:
C07C59/68; C07C59/70; C07D207/337; C07D209/42; C07D235/28; C07D239/22; C07D307/68; C07D317/60; C07D471/04; C07D493/04; G01N27/447; G01N33/5011; G01N2333/47
Patent application
3409
德國
